Credit Suisse Group reiterated their outperform rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a report issued on Thursday, Marketbeat reports. The firm currently has a $147.00 price objective on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently issued reports on ALXN. Leerink Swann reiterated a buy rating and issued a $182.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a buy rating to a hold rating in a research report on Monday, October 2nd. Piper Jaffray Companies reiterated an overweight rating and issued a $170.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Stifel Nicolaus cut their target price on shares of Alexion Pharmaceuticals from $165.00 to $159.00 and set a buy rating for the company in a research report on Tuesday, October 24th. Finally, Royal Bank of Canada increased their target price on shares of Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $153.10.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $0.70 during trading hours on Thursday, hitting $121.05. 1,747,222 shares of the company traded hands, compared to its average volume of 2,100,000. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. The stock has a market cap of $27,040.00, a P/E ratio of 54.04, a PEG ratio of 1.01 and a beta of 1.17. Alexion Pharmaceuticals has a fifty-two week low of $96.18 and a fifty-two week high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business had revenue of $859.00 million during the quarter, compared to the consensus estimate of $864.34 million. During the same quarter in the prior year, the firm earned $1.23 EPS. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. sell-side analysts predict that Alexion Pharmaceuticals will post 4.82 EPS for the current year.
In other news, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares in the company, valued at approximately $4,399,600.36. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.35% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Alexion Pharmaceuticals by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 14,785,831 shares of the biopharmaceutical company’s stock worth $1,798,992,000 after purchasing an additional 318,375 shares during the last quarter. State Street Corp increased its stake in shares of Alexion Pharmaceuticals by 5.0% during the 2nd quarter. State Street Corp now owns 11,860,647 shares of the biopharmaceutical company’s stock worth $1,443,099,000 after purchasing an additional 561,962 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Alexion Pharmaceuticals by 3.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after buying an additional 215,005 shares during the last quarter. Jennison Associates LLC grew its stake in Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after buying an additional 4,682,336 shares during the last quarter. Finally, Northern Trust Corp grew its stake in Alexion Pharmaceuticals by 17.2% in the 2nd quarter. Northern Trust Corp now owns 2,966,636 shares of the biopharmaceutical company’s stock valued at $360,950,000 after buying an additional 435,482 shares during the last quarter. Institutional investors own 94.27% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Credit Suisse Group Reaffirms Outperform Rating for Alexion Pharmaceuticals (ALXN)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/21/credit-suisse-group-reaffirms-outperform-rating-for-alexion-pharmaceuticals-alxn.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.